Oral Thin Films Market, 2015 - 2025

  • Lowest Price Guaranteed From USD 1,899

  • Published
    January 2015

  • Pages
    249

  • View Count
    10501

  • Buy Now

Example Insights

  1. There are 10 prescription oral thin films currently in the market. In addition, there are 29 such films which are currently in different stages of clinical / pre-clinical development. Of these, six products are expected to get launched in 2015 / 2016 in their respective geographies.
  2. Approximately 54% of these products are oral transmucosal thin films. These films can be administered through sublingual, buccal or oral mucosal route, providing advantage of rapid onset of action.
  3. A number of these products (approx. 38%) are based on either MonoSol’s PharmFilm technology or Applied Pharma Research / Labtec’s RapidFilm technology. In addition to these two, there are over 10 other proprietary oral thin film technologies; some of these are currently being utilized for formulating over-the-counter products.
  4. Some start-ups such as FFT Medical and Cynapsus Therapeutics have also recently emerged; these new companies are coming up with their oral transmucosal thin film products and are likely to foster more innovation in the coming few years.
  5. Of all the marketed products, Suboxone film has found a strong acceptance in a short span of time; other marketed products such as Breakyl, Onsolis and Zuplenz are also gaining ground in different geographies. Overall, as more products get launched, we expect the market to sustain the growth momentum.

Overview

Oral drug delivery technologies form an integral part of the pharmaceutical industry. From the conventional tablets / capsules to modern-day fast disintegrating and rapidly acting tablets / films, the market has come a long way. Lower bioavailability of oral solid drugs, inconvenience of administering injections, inaccurate dosing by liquid formulations have turned the focus of pharmaceutical companies to develop novel oral dosage forms that eliminate several known limitations. In addition, dysphagia, a common problem due to difficulty in swallowing in people of all ages, especially paediatric, geriatric, psychiatric, uncooperative and nauseated patients, has led to increase in demand of an alternative dosage form that provides rapid dissolution without the need of water and rapid onset of action when delivered through oral mucosa.

Oral thin films are able to meet most of these challenges. The concept isn’t new and several over-the-counter oral thin films are readily available. Good acceptance from the users and an increasing demand of over-the-counter oral film products has led to the development of prescription drugs into oral thin films. These films not only offer a range of benefits to specific patient population segments but also provide a number of additional benefits to other stakeholders in the industry. The emerging area has gained attention from both established and start- up pharmaceutical firms.

Companies are utilizing their oral thin film technologies to develop different types of oral thin films (e.g. oral dispersible, sublingual, buccal). In addition to the drugs, several hormones and vaccines are also being formulated into oral thin films with the aim of providing improved patient compliance. Some of the key players in this area include MonoSol Rx, Applied Pharma Research/ Labtec GmbH, BioDelivery Sciences and NAL Pharma. Many companies are collaborating with these technology providers and utilizing oral thin films as a life cycle management tool for their branded drugs that have lost patent in other dosage forms.

There are not many prescription oral thin films currently available in the market; however, the pipeline holds a wider promise. Despite the uncertainties related to the development, approval and penetration rate, the market is likely to witness stable growth in the coming decade.

 

Scope of the Report

The ‘Oral Thin Films’ market report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Starting with the basic introduction to the oral transmucosal route, its advantages and disadvantages, the report lays emphasis on the unmet needs fulfilled by oral thin films. Although oral thin films have been available in the forms of breath freshening strips, vitamin strips and other over-the-counter products for the past few decades, pharmaceutical companies have recently directed their focus towards formulating prescription products into oral thin films.

The study includes all prescription oral thin films, not necessarily delivered through oral mucosa. For these products, we have provided detailed profiles, underlying technologies being used to develop them and information on the key companies leading the efforts. We have also provided a detailed view on the key drivers behind the growth of this market, likely challenges and upcoming threats under the SWOT framework.

Many patients primarily paediatric, geriatric and dysphasia find it difficult to swallow traditional tablets and capsules. Moreover, some diseases require rapid onset of action. This is possible through injections; some patients, though, find it inconvenient and painful to administer injections. Oral thin films provide the best alternative dosage form for administering drug for such patients. It is important to highlight that not many prescription oral thin film products are commercially available yet. Several companies are developing innovative technologies to formulate oral thin films, which provide the advantage of rapid dissolution without the need of water and rapid onset of action when delivered through mucosa.

Given the specific advantages offered by these films and their ability to overcome the current unmet needs, the future holds significant potential. In fact, one of the primary objectives of this report is to estimate size of this future promise offered by marketed oral thin films and those currently under development. We have identified the sales potential of various oral thin films for the period 2015 - 2025. Owing to the uncertain nature of this market, we have presented three scenarios for our market forecast; these scenarios represent different growth tracks of the industry likely to be influenced by variable adoption, pricing and the evolving competitive landscape.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of oral thin films market.

Chapter 3  provides a general introduction to the oral transmucosal route, covering details on different oral mucosal sites including the most common sublingual and buccal. The chapter also talks about the various sublingual and buccal dosage forms available in the market.

Chapter 4  provides an introduction to oral thin films, their features, advantages and disadvantages. The chapter provides details on the composition, manufacturing methods, storage and packaging of the oral thin films.

Chapter 5  highlights various developments which have taken place in the field of oral thin films. We have looked at prescription oral thin films (both marketed and in different stages of development) and some of the most common over-the-counter oral thin films. The chapter also lists the various technologies which are being used by pharmaceutical companies for developing oral thin films.

Chapter 6  provides detailed profiles on various drugs and vaccines being targeted for formulation into oral thin films. Starting with the introduction, these profiles cover historical developments of specific drugs / vaccines in other dosage forms, target population, historical sales and recent developments.

Chapter 7  looks at the future state of oral thin films market till 2025. It highlights the leading oral thin film products which are likely to drive the upcoming growth and the relative market size of oral thin films in terms of sales.

Chapter 8  provides the SWOT analysis of oral thin films market giving strategic insights to the major factors that are likely to contribute to future growth while also highlighting the weakness and threats that can negatively impact the evolution.

Chapter 9  includes profiles of the key companies active in this market. It covers detailed information on the technology provided by the each company, financial performance, marketed / pipeline products, recent developments, collaborations and future growth plans.

Chapter 10  summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in the previous chapters.

Chapter 11  is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 12  is an appendix, which provides a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. ORAL TRANSMUCOSAL DRUG DELIVERY
3.1. Chapter Overview
3.2. Oral Route
3.3. Oral Transmucosal Route
3.3.1. Sublingual Administration
3.3.2. Buccal Administration
3.3.3. Local Administration
3.4. Mechanism Involved in Oral Transmucosal Drug Administration
3.5. Advantages of Oral Transmucosal Drug administration
3.6. Disadvantages of Oral Transmucosal Drug Administration
3.7. Sublingual and Buccal Dosage Forms
3.7.1. Sublingual Tablet Forms
3.7.2. Buccal Tablet Forms
3.7.3. Sublingual and Buccal Oral Thin Films
3.7.4. Sublingual Immunotherapy (SLIT) / Sublingual Drops
3.7.5. Buccal Bioadhesive Patches
 
4. ORAL THIN FILMS
4.1. Chapter Overview
4.2. Emergence of Oral Thin Films
4.3. Oral Thin Films: Definition and Classification
4.3.1. Classification by Absorption Site
4.3.2. Classification by Properties / Wafer Type
4.3.3. Mechanism of Action
4.3.4. Features of an Ideal Oral Thin Film
4.3.5. Ideal Characteristics of Suitable Drug Candidates
4.4. Composition / Ingredients of Oral Thin Films
4.4.1. Active Pharmaceutical Ingredients
4.4.2. Water Soluble Polymers
4.4.3. Plasticizers
4.4.4. Saliva Stimulating Agents
4.4.5. Sweetening and Flavouring Agents
4.4.6. Surfactants and Colouring Agents
4.4.7. Permeation Enhancers
4.4.8. Stabilizing and Thickening Agents
4.5. Manufacturing Methods for Oral Thin Films
4.5.1. Solvent Casting Method
4.5.2. Semisolid Casting Method
4.5.3. Hot Melt Extrusion Method
4.5.4. Solid Dispersion Extrusion Method
4.5.5. Rolling Method
4.6. Storage and Packaging of Oral Thin Films
 
5. OVERVIEW AND MARKET BACKGROUND
5.1. Chapter Overview
5.2. Over-the-Counter Oral Thin Film Products
5.3. Technology and Technology Providers
5.4. Prescription Oral Thin Film Products
5.4.1. Distribution by Type of Oral Thin Film
5.4.2. Distribution by Type of Product
5.4.3. Distribution by Type of Technology
5.4.4. Distribution by Development Status
5.5. Manufacturing Facilities for Oral Thin Films
5.6. Packaging Facilities for Oral Thin Films
 
6. PRODUCT PROFILES
6.1. Chapter Overview
6.2. Adrenalin
6.2.1. Overview
6.2.2. Development History
6.2.3. Dosage Forms of Adrenalin
6.2.4. Target Population
6.2.5. Adrenalin Sales
6.2.6. Oral Thin Film Formulation of Adrenalin
6.2.6.1. Adrenalin Oral Transmucosal Thin Film
 
6.3. Apomorphine
6.3.1. Overview
6.3.2. Development History
6.3.3. Dosage Forms of Apomorphine
6.3.4. Oral Thin Film Formulation of Apomorphine
6.3.4.1. APL-130277
6.3.5. Target Population
6.3.6. Apomorphine Sales
 
6.4. Aripiprazole
6.4.1. Overview
6.4.2. Development History
6.4.3. Dosage Forms of Aripiprazole
6.4.4. Target Population
6.4.5. Aripiprazole Sales
6.4.6. Aripiprazole RapidFilm
 
6.5. Buprenorphine (Single / Combination)
6.5.1. Overview
6.5.2. Development History
6.5.3. Dosage Forms of Buprenorphine (Single / Combination)
6.5.4. Target Population
6.5.5. Oral Thin Formulation of Buprenorphine (Single / Combination)
6.5.5.1. Suboxone Film (Buprenorphine and Naloxone)
6.5.5.2. Bunavail (Buprenorphine and Naloxone)
6.5.5.3. BEMA Buprenorphine
6.5.6. Buprenorphine Sales
 
6.6. Donepezil
6.6.1. Overview
6.6.2. Development History
6.6.3. Dosage Forms of Donepezil
6.6.4. Target Population
6.6.5. Oral Thin Film Formulation of Donepezil
6.6.5.1. Donepezil RapidFilm
6.6.5.2. NAL8817
6.6.6. Donepezil Sales
 
6.7. Fentanyl
6.7.1. Overview
6.7.2. Development History
6.7.3. Dosage Forms of Fentanyl
6.7.4. Oral Thin Film Formulation of Fentanyl
6.7.4.1. Onsolis
6.7.4.2. Breakyl
6.7.4.3. Painkyl
6.7.4.4. Fastanix/ NAL1239
6.7.5. Fentanyl Sales
 
6.8. Flu/Influenza Vaccine
6.8.1. Overview
6.8.2. Dosage Forms of Flu/Influenza Vaccine
6.8.3. Target Population
6.8.4. Flu/Influenza Vaccine Sales
6.8.5. Oral Thin Film Formulation of Flu/Influenza Vaccine
 
6.9. Insulin
6.9.1. Overview
6.9.2. Dosage Forms of Insulin
6.9.3. Target Population
6.9.4. Insulin Sales
6.9.5. Oral Thin Film Formulation of Insulin
6.9.5.1. MidaForm Insulin PharmFilm
 
6.10. Levodopa
6.10.1. Overview
6.10.2. Development History
6.10.3. Dosage Forms of Levodopa / Carbidopa
6.10.4. Target Population
6.10.5. Levodopa/ Carbidopa Sales
6.10.6. Oral Thin Film Formulation of Levodopa
6.10.6.1. Levodopa Oral Transmucosal Thin Film
 
6.11. Montelukast Sodium
6.11.1. Overview
6.11.2. Development History
6.11.3. Dosage Forms of Montelukast Sodium
6.11.4. Target Population
6.11.5. Montelukast Sodium Sales
6.11.6. Oral Thin Film Formulation of Montelukast Sodium
6.11.6.1. Montelukast Sodium PharmFilm
6.11.6.2. NAL6336
 
6.12. Olanzapine
6.12.1. Overview
6.12.2. Development History
6.12.3. Dosage Forms of Olanzapine
6.12.4. Target Population
6.12.5. Olanzapine RapidFilm
6.12.6. Olanzapine Sales
 
6.13. Ondansetron
6.13.1. Overview
6.13.2. Development History
6.13.3. Target Population
6.13.4. Oral Thin Film Formulation of Ondansetron
6.13.4.1. Zuplenz
6.13.4.2. Setofilm
6.13.4.3. Ondissolve
6.13.5. Ondansetron Sales
 
6.14. Penicillin G
6.14.1. Overview
6.14.2. Dosage Forms of Penicillin G
6.14.3. Penicillin G Sales
6.14.4. Oral Thin Film Formulation of Penicillin G
6.14.4.1. Penicillin G Oral Transmucosal Thin Film
 
6.15. Rizatriptan
6.15.1. Overview
6.15.2. Development History
6.15.3. Dosage Forms of Rizatriptan
6.15.4. Target Population
6.15.5. Rizatriptan Sales
6.15.6. Oral Thin Formulation of Rizatriptan
6.15.6.1. MSRX-202
6.15.6.2. Rizaport
6.15.6.3. NAL1606
 
6.16. Rotavirus Vaccine
6.16.1. Overview
6.16.2. Development History
6.16.3. Dosage Forms of Rotavirus Vaccine
6.16.4. Target Population
6.16.5. Rotavirus Vaccine Sales
6.16.6. Oral Thin Film Formulation of Rotavirus Vaccine
6.16.6.1. Aridis Pharmaceuticals
6.16.6.2. Hilleman Laboratories
 
6.17. Testosterone
6.17.1. Overview
6.17.2. Dosage Forms of Testosterone
6.17.3. Target Population
6.17.4. Testosterone Sales
6.17.5. Oral Thin Film Formulation of Testosterone
6.17.5.1. MSRX-110
 
6.18. Zolmitriptan
6.18.1. Overview
6.18.2. Development History
6.18.3. Dosage Forms of Zolmitriptan
6.18.4. Target Population
6.18.5. Oral Thin Film Formulation of Zolmitriptan
6.18.5.1. Zolmitriptan RapidFilm
6.18.6. Zolmitriptan Sales
 
7. MARKET FORECAST
7.1. Chapter Overview
7.2. Scope and Limitations
7.3. Forecast Methodology
7.4. Overall Oral Thin Films Market, 2015-2025
7.5. Buprenorphine and Naloxone:Suboxone film (MonoSol Rx) and Bunavail (BioDelivery Sciences)
7.5.1. Suboxone film and Bunavail Sales Forecast: Short-Mid Term, 2015-2020
7.5.2. Suboxone film and Bunavail Sales Forecast: Long Term, 2020-2025
7.6. Fentanyl (BioDelivery Sciences): Onsolis (US), Breakyl (EU) and Painkyl (Canada)
7.6.1. Fentanyl Oral Thin Film Sales Forecast: Short-Mid Term, 2015-2020
7.6.2. Fentanyl Oral Thin Film Sales Forecast: Long Term, 2020-2025
7.7. Ondansetron: Zuplenz (MonoSol Rx), Setofilm (Applied Pharma Research and Labtec) and Ondissolve (Applied Pharma Research and Labtec)
7.7.1. Ondansetron Oral Thin Film Sales Forecast: Short-Mid Term, 2015-2020
7.7.2. Ondansetron Oral Thin Film Sales Forecast: Long Term, 2020-2025
7.8. Olanzapine: Olanzapine RapidFilm (Applied Pharma Research and Labtec)
7.8.1. Olanzapine RapidFilm Sales Forecast: Short-Mid Term, 2015-2020
7.8.2. Olanzapine RapidFilm Sales Forecast: Long Term, 2020-2025
7.9. Donepezil: Donepezil RapidFilm (Applied Pharma Research and Labtec)
7.9.1. Donepezil RapidFilm Sales Forecast: Short-Mid Term, 2015-2020
7.9.2. Donepezil RapidFilm Sales Forecast: Long Term, 2020-2025
7.10. Zolmitriptan: Zolmitriptan RapidFilm (Applied Pharma Research and Labtec)
7.10.1. Zolmitriptan RapidFilm Sales Forecast: Short-Mid Term, 2015-2020
7.10.2. Zolmitriptan RapidFilm Sales Forecast: Long Term, 2020-2025
7.11. Rizatriptan: Rizaport (IntelGenX)
7.11.1. Rizaport Sales Forecast: Short-Mid Term, 2016-2020
7.11.2. Rizaport Sales Forecast: Long Term, 2020-2025
7.12. Buprenorphine:BEMA Buprenorphine (BioDelivery Sciences)
7.12.1. BEMA Buprenorphine Sales Forecast: Short-Mid Term, 2016-2020
7.12.2. BEMA Buprenorphine Sales Forecast: Long Term, 2020-2025
7.13. Montelukast Sodium: Montelukast Sodium PharmFilm (MonoSol Rx)
7.13.1. Montelukast Sodium PharmFilm Sales Forecast: Short-Mid Term, 2016-2020
7.13.2. Montelukast Sodium PharmFilm Sales Forecast: Long Term, 2020-2025
 
8. SWOT ANALYSIS
 
9. COMPANY PROFILES
9.1. MonoSol Rx
9.2. tesa Labtec GmbH
9.3. IntelGenX
9.4. BioDelivery Sciences
9.5. Cynapsus Therapeutics
9.6. FFT Medical
9.7. Innoteq
9.8. Adhesives Research
 
10. CONCLUSION
10.1. Oral Thin Films: Significant Advantages and Major Drivers
10.2. Emergence of New Technologies
10.3. Market is Still Emerging; Launch of New Products Will Sustain the Momentum
10.4. Overall Opportunity is Big
10.5. Concluding Remarks
 
11. APPENDIX 1: TABULATED DATA
 
12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 4.1 Classification by Absorption Site
Figure 5.1 Oral Thin Films: Distribution by Type
Figure 5.2 Oral Transmucosal Thin Films: Distribution by Absorption Site
Figure 5.3 Oral Thin Films: Distribution by Type of Product
Figure 5.4 Oral Thin Films: Distribution by Type of Technology
Figure 5.5 Oral Thin Films: Distribution by Development Status
Figure 6.1 Total Adrenalin Sales (USD Million)
Figure 6.2 Total Apomorphine Hydrochloride Sales (USD Million)
Figure 6.3 Total Aripiprazole Sales (USD Million)
Figure 6.4 Total Abilify Sales (USD Million)
Figure 6.5  Historical Development of Buprenorphine (Single / Combination)
Figure 6.6  Opioid User Composition of Regions Outside the US (Million)
Figure 6.7  Total Suboxone Film Sales (USD Million)
Figure 6.8  Suboxone Film: Sales and Market Share in the US (USD Billion)
Figure 6.9  Prevalence of Alzheimer’s Disease in the US: Distribution by Age
Figure 6.10  Total Donepezil Hydrochloride Sales (USD Million)
Figure 6.11  Aricept Sales by Eisai (JPY Billion)
Figure 6.12  Aricept Sales by Pfizer (USD Million)
Figure 6.13  Total Fentanyl Sales (USD Million)
Figure 6.14  Total Fentanyl Citrate Sales (USD Million)
Figure 6.15  Total Fentanyl Transdermal System Sales (USD Million)
Figure 6.16  Total Influenza Vaccine Sales (USD Million)
Figure 6.17  Total Levodopa / Carbidopa Sales (USD Million)
Figure 6.18  Total Montelukast Sodium Sales (USD Million)
Figure 6.19  Total Singulair Sales (USD Million)
Figure 6.20  Total Olanzapine Sales (USD Million)
Figure 6.21  Total Zyprexa Sales (USD Million)
Figure 6.22  Historical Development of Ondansetron
Figure 6.23  Total Penicillin G Benzathine Sales (USD Million)
Figure 6.24  Total Penicillin G Potassium Sales (USD Million)
Figure 6.25  Total Rizatriptan Benzoate Sales (USD Million)
Figure 6.26  Total Maxalt Sales (USD Million)
Figure 6.27  Total Rotavirus Vaccine Sales (USD Million)
Figure 6.28  Total Zolmitriptan Sales (USD Million)
Figure 6.29  Total Zomig Sales (USD Million)
Figure 7.1 Overall Oral Thin Films Market (USD Million), 2015-2025 (Base Scenario)
Figure 7.2  Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.3  Suboxone film and Bunavail Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.4  Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.5  Fentanyl Oral Thin Film Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.6  Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.7  Ondansetron Oral Thin Film Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.8    Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.9  Olanzapine RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.10  Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.11 Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.12  Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.13 Zolmitriptan RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.14  Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Figure 7.15  Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.16  BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Figure 7.17  BEMA Buprenorphine Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.18 Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Figure 7.19  Montelukast Sodium PharmFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 9.1  IntelGenX Revenues, 2007-2013(USD Million)
Figure 9.2  BioDelivery Sciences Revenues, 2009-2013 (USD Million)
Figure 10.1  Oral Thin Films Market (USD Million): 2015, 2020, 2025

List of Tables

Table 4.1 Classification by Properties/Wafer Type
Table 4.2  Composition of Oral Thin Films
Table 5.1  Over-the-Counter Oral Thin Films: Marketed and Pipeline Products
Table 5.2  Oral Thin Film Technologies
Table 5.3  Prescription Oral Thin Films: Marketed and Pipeline Products
Table 5.4  Manufacturing Facilities for Oral Thin Films
Table 5.5  Companies Offering Packaging Facilities for Oral Thin Films
Table 6.1  Active Ingredients Formulated in Oral Thin Films
Table 6.2  Adrenalin Self Administering Delivery Systems
Table 6.3  Apomorphine Brand Names
Table 6.4  APL-130277 Phase II Results
Table 6.5  Abilify: Approval History
Table 6.6  Aripiprazole Dosage Forms
Table 6.7  Buprenorphine: Pharmacokinetics Characteristics 
Table 6.8  Buprenorphine Dosage Forms
Table 6.9  Comparison between Buprenorphine Transmucosal Dosage Forms
Table 6.10  Brand Names of Buprenorphine (Single / Combination) Thin Films
Table 6.11 BEMA Buprenorphine: Completed Phase III Efficacy Studies
Table 6.12  Donepezil Dosage Forms
Table 6.13  Fentanyl Dosage Forms
Table 6.14  Comparison of Various Fentanyl Transmucosal Dosage Forms
Table 6.15  Oral Thin Film Fentanyl Brands
Table 6.16  Levodopa / Carbidopa Dosage Forms
Table 6.17  Montelukast Sodium Dosage Forms
Table 6.18  Olanzapine Dosage Forms
Table 6.19  Brand Names of Ondansetron Oral Thin Films
Table 6.20  Penicillin G: Derivatives and Dosage Forms
Table 6.21  Rizatriptan Dosage Forms
Table 6.22  Testosterone Dosage Forms
Table 6.23  Zolmitriptan Dosage Forms
Table 7.1  Oral Thin Film Based Products: Market Availability/Expected Launch Year
Table 8.1  SWOT Analysis
Table 8.2 Drugs that have Lost / will Lose Patent in 2014, 2015, 2016
Table 9.1  MonoSol Rx Product Portfolio
Table 9.2  Labtec Oral Dispersible Film Product Portfolio
Table 9.3  IntelGenX Product Portfolio 
Table 9.4  BioDelivery Sciences Product Portfolio
Table 9.5  FFT Medical Product Portfolio
Table 11.1  Oral Thin Films: Distribution by Type
Table 11.2  Oral Transmucosal Thin Films: Distribution by Absorption Site
Table 11.3  Oral Thin Films: Distribution by Type of Product
Table 11.4  Oral Thin Films: Distribution by Type of Technology
Table 11.5  Oral Thin Films: Distribution by Development Status
Table 11.6  Total Adrenalin Sales (USD Million)
Table 11.7  Total Apomorphine Hydrochloride Sales (USD Million)
Table 11.8  Total Aripiprazole Sales (USD Million)
Table 11.9  Total Abilify Sales (USD Million)
Table 11.10  Opioid User Composition of Regions Outside the US (Million)
Table 11.11  Total Suboxone Film Sales (USD Million)
Table 11.12  Suboxone Film: Sales and Market Share in the US (USD Billion)
Table 11.13  Prevalence of Alzheimer’s Disease in the US: Distribution by Age
Table 11.14  Total Donepezil Hydrochloride  Sales (USD Million)
Table 11.15  Aricept Sales by Eisai(JPY Billion)
Table 11.16  Aricept Sales by Pfizer (USD Million)
Table 11.17  Total Fentanyl Sales (USD Million)
Table 11.18  Total Fentanyl Citrate Sales (USD Million)
Table 11.19  Total Fentanyl Transdermal System Sales (USD Million)
Table 11.20  Total Influenza Vaccine Sales (USD Million)
Table 11.21  Total Levodopa / Carbidopa Sales (USD Million)
Table 11.22  Total Montelukast Sodium Sales (USD Million)
Table 11.23  Total Singulair Sales (USD Million)
Table 11.24  Total Olanzapine Sales (USD Million)
Table 11.25  Total Zyprexa Sales (USD Million)
Table 11.26  Total Penicillin G Benzathine Sales (USD Million)
Table 11.27  Total Penicillin G Potassium Sales (USD Million)
Table 11.28  Total Rizatriptan Benzoate Sales (USD Million)
Table 11.29  Total Maxalt Sales (USD Million)
Table 11.30  Total Rotavirus Vaccine Sales (USD Million)
Table 11.31  Total Zolmitriptan Sales (USD Million)
Table 11.32  Total Zomig Sales (USD Million)
Table 11.33 Overall Oral Thin Films Market (USD Million), 2015-2025 (Base Scenario)
Table 11.34  Overall Oral Thin Films Market (USD Million), 2015-2025 (Conservative Scenario)
Table 11.35  Overall Oral Thin Films Market (USD Million), 2015-2025 (Optimistic Scenario)
Table 11.36  Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.37  Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.38  Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.39  Suboxone film and Bunavail Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.40  Suboxone film and Bunavail Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.41  Suboxone film and Bunavail Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.42  Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.43  Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.44  Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.45  Fentanyl Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.46  Fentanyl Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.47  Fentanyl Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.48  Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.49  Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.50  Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.51  Ondansetron Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.52  Ondansetron Oral Thin Film Sales Forecast (USD Million):Long Term, 2020 -2025 (Conservative Scenario)
Table 11.53  Ondansetron Oral Thin Film Sales Forecast (USD Million): Long Term, 2020-2025 (Optimistic Scenario)
Table 11.54  Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.55  Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.56    Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.57  Olanzapine RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.58  Olanzapine RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.59  Olanzapine RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.60  Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.61  Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.62  Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.63  Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Table 11.64  Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Conservative Scenario)
Table 11.65  Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Optimistic Scenario)
Table 11.66  Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.67  Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.68  Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.69  Zolmitriptan RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.70  Zolmitriptan RapidFilm Sales Forecast (USD Million):LongTerm, 2020-2025 (Conservative Scenario)
Table 11.71  Zolmitriptan RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.72  Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Table 11.73  Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Conservative Scenario)
Table 11.74  Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Optimistic Scenario)
Table 11.75  Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Table 11.76  Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Conservative Scenario)
Table 11.77  Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Optimistic Scenario)
Table 11.78  BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Table 11.79  BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Conservative Scenario)
Table 11.80  BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Optimistic Scenario)
Table 11.81  BEMA Buprenorphine Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.82  BEMA Buprenorphine Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.83  BEMA Buprenorphine Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.84  Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Table 11.85  Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Conservative Scenario)
Table 11.86  Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Optimistic Scenario)
Table 11.87  Montelukast Sodium PharmFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.88  Montelukast Sodium PharmFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.89  Montelukast Sodium PharmFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.90  IntelGenX Revenues, 2007-2013(USD Million)
Table 11.91  BioDelivery Sciences Revenues, 2009-2013 (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. Aavishkar
  2. Abdi Ibrahim Pharmaceuticals
  3. Actavis
  4. Actavis Pharma
  5. Adagio Pharmaceuticals
  6. Adhesives Research
  7. ALK Lifeline
  8. Amcor Flexibles
  9. Apotek Produktion and Laboratorier
  10. ApotheekZorg
  11. Applied Pharma Research
  12. Archimedes
  13. Arcion Therapeutics
  14. Aridis Pharmaceuticals
  15. AstraZeneca
  16. Aurobindo Pharma
  17. Aveva Drug Delivery Systems 
  18. Baxter Healthcare 
  19. Bharat Biotech
  20. BioAlliance Pharma
  21. BioDelivery Sciences
  22. BioFilm 
  23. BiondVax Pharmaceuticals 
  24. Bristol-Myers Squibb
  25. Buccal Pharma
  26. C.L Pharm
  27. Cadila Pharmaceuticals
  28. Cipla
  29. Clonmel Healthcare
  30. Cure Pharmaceuticals
  31. Cynapsus Therapeutics 
  32. Dr. Reddy’s Laboratories
  33. Edgemont Pharmaceuticals
  34. Eisai
  35. Eli Lilly 
  36. Endo Pharmaceuticals
  37. Engineered Production Equipment
  38. Ethypharm
  39. Ferrer Internacional
  40. FFT Medical
  41. Galena Biopharma
  42. Galenix Innovations
  43. Gammatec
  44. Gen Ilac
  45. Genus Pharmaceuticals
  46. GlaxoSmithKline
  47. Hikma Pharmaceuticals
  48. Hilleman Laboratories  
  49. Hospira
  50. Huahai US
  51. Impax Pharmaceuticals
  52. Innoteq
  53. InnoZen
  54. Insys Therapeutics
  55. IntelGenX
  56. Italfarmaco
  57. ITF Hellas
  58. J-Pac Medical 
  59. Jubilant Generics
  60. Jubilant Life Sciences
  61. KemPharm
  62. Kunwha Pharmaceutical Co. Ltd
  63. Laboratoire Aguettant
  64. LaviPharm
  65. Licher MT
  66. Lincoln Medical
  67. LTS Lohmann Therapie-Systeme AG 
  68. Macleods Pharmaceuticals
  69. Macular Health
  70. Matrix Laboratories
  71. Meda A.B
  72. Meda Pharmaceuticals
  73. Meda Valeant Pharma Canada Inc.
  74. Merck
  75. MidaSol Therapeutics 
  76. MonoSol Rx
  77. Mylan Pharmaceuticals
  78. NAL Pharma
  79. NeuroHealing Pharmaceuticals
  80. NordicInfu Care
  81. Norgine
  82. Novartis
  83. ODF Pharma 
  84. Orexo AB 
  85. Otsuka Pharmaceuticals
  86. Pace Wellness 
  87. Par Pharmaceutical
  88. Pediology
  89. Pfizer
  90. Pliva Hrvatska
  91. Quintiles
  92. Ranbaxy
  93. Reckitt Benckiser Pharmaceuticals
  94. RedHill Biopharma
  95. Renantos Pharmavertriebsges. mbH
  96. Roxane-
  97. Sandoz
  98. Sanofi Pasteur 
  99. Sato Pharmaceuticals
  100. SciClone Pharmaceuticals
  101. Sciele Pharma
  102. Sharp Packaging Services
  103. Stada Asia
  104. Strativa Pharmaceuticals
  105. Sun Pharmaceutical
  106. Takeda
  107. tesa Labtec GmbH
  108. Teva Pharmaceuticals
  109. Torrent Pharmaceuticals
  110. TTY Biopharm
  111. US WorldMeds
  112. Vestiq Holdings
  113. Wansår Corporation
  114. Wockhardt
  115. Wyeth
  116. Zengen
  117. Zydus

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.